Pfizer Inc. and Eli Lilly and Company announced the call for proposals for the 1st Global Awards for Advancing Chronic Pain Research (ADVANCE) in 2018. ADVANCE is a competitive awards program and will provide a unique opportunity for Pfizer Inc. and Eli Lilly and Company to support chronic pain research at medical and research institutions throughout the world. Proposals will be reviewed by an external multidisciplinary, Independent Review Committee comprising renowned, global experts in chronic pain. The assessment process is completely independent of Pfizer Inc. and Eli Lilly and Company, with final responsibility for selection of Awardees resting with the Co-Chairs. The intent of the program is to fund approximately 5 grants between US $50,000 to US $200,000 for a total fund of US $1 million.
For further information about ADVANCE, including areas of research that are considered in-scope and how to apply, come visit www.advanceresearchawards-chronicpain.com
Deadline: July 12, 2018